AstraZeneca is a global, science-led, patient-focused biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines for some of the world’s most serious diseases! We are more than one of the world’s leading pharmaceutical companies. AstraZeneca has an engaging environment that cultivates collaboration and innovation. We attract top minds, and we cultivate and build talent. Within Hematology R&D, we are committed to advancing the science to deliver life changing medicines to patients most in need. With a combination-focused pipeline that exploits the power of six scientific platforms (Immuno-Oncology, Tumor Drivers and Resistance, DNA Damage Response, Antibody-drug Conjugates, Cell Therapy and Epigenetics) to help address unmet clinical needs in a host of hematological cancers, we are motivated by a dedication to the scientific discovery and collaboration that will one day help eliminate cancer as a cause of death. This unit has responsibility for the value chain from discovery through to late-stage development, enabling rapid acceleration of promising early-stage assets and life-cycle management programs Translational Medicine (TM) overview Translational Medicine transforms hematological cancer biology into actionable insights for therapeutic development and clinical decision-making within the Oncology space. Operating within the Hematology R&D division, TM is responsible for delivering innovative, strategic biomarker studies to support Hematology & Oncology project teams to make decisions. The TM team collaborates closely with preclinical bioscience and discovery, early clinical development, and precision medicine & Biosamples functions. TM provides robust, scientifically driven biomarkers for all Hematology projects covering leukemia, lymphoma and myeloma. This includes assay development, technical validation, and biomarker analysis for clinical samples. TM conducts translational research across early and late-phase clinical engagements, integrating advanced biomarker strategies to enhance therapeutic outcomes. The Translational Research (TR) group is responsible for delivering laboratory assay development across our drug programs and impactful translational insights across our high priority cancer types Key Responsibilities and Accountabilities The Associate Director plays an integral role leading a small team in the development of translational assays, delivery of translational data, and hands-on execution of critical translational experiments and projects that support the Heme Translational Medicine Department’s strategy. This includes clinical trial support, pre-clinical drug development, and cross-indication delivery. The Associate Director will have a special focus on supporting programs in multiple myeloma and blood cancer precursor conditions. The AD is responsible for the design and execution of non-clinical and translational experiments to understand hematological tumor biology, supporting the AZ portfolio. This work includes, but is not limited to, testing target expression after treatment, novel MRD technologies, reverse translation approaches to identify mechanisms of resistance, and informing new combinations across multiple heme indications.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Mid Level
Education Level
Ph.D. or professional degree
Number of Employees
5,001-10,000 employees